3-keto HMG-CoA reductase inhibitors

ABSTRACT

Compounds of formula (I) and (II): ##STR1## are HMG-CoA reductase inhibitors.

This is a division of application Ser. No. 363,792 filed June 9, 1989now U.S. Pat. No. 4,968,693, which is a CIP of Ser. No. 07/162,785 filed3/22/88, now abandoned.

BACKGROUND OF THE INVENTION

Hypercholesterolemia is known to be one of the prime risk factors forischemic cardiovascular disease, such as arteriosclerosis. Bile acidsequestrants have been used to treat this condition; they seem to bemoderately effective but they must be consumed in large quantities, i.e.several grams at a time and they are not very palatable.

MEVACOB™ (lovastatin), now commercially available, is one of a group ofvery active antihypercholesterolemic agents that function by limitingcholesterol biosynthesis by inhibiting the enzyme, HMG-CoA reductase. Inaddition to the natural fermentation products, mevastatin andlovastatin, there are a variety of analogs thereof, produced bymicrobial, enzymatic and synthetic techniques.

The naturally occurring compounds and their analogs have the followinggeneral structural formulae: ##STR2## wherein:

R¹ is hydrogen, C₁₋₅ alkyl or C₁₋₅ alkyl substituted with a member ofthe group consisting of phenyl, dimethylamino, or acetylamino; and

R^(*) is ##STR3## wherein

Q is ##STR4## or ##STR5## R³ is H or OH or Q is ##STR6##

M is --CHR⁴, R⁴ is hydrogen or hydroxy; X is CR⁵ R⁶, O, S, or NH; R⁵ andR⁶ are H, OH, or OR⁷ where R⁷ represents a phosphoryl or acyl moiety;

R² is hydrogen or methyl; and a, b, c, and d represent single bonds, oneof a, b, c or d represents a double bond, or both a and c or both b andd represent double bonds provided that when a is a double bond, Q is##STR7## and when d is a double bond, M is ##STR8## and provided thatwhen R⁵ or R⁶ is OH or OR⁷ or X is O, S, or NH, a, b, and c are singlebonds.

U.S. Pat. No. 4,517,373 discloses hydroxy containing compoundsrepresented by the above general formula wherein R^(*) is ##STR9##

U.S. Pat. No. 4,537,859 and U.S. Pat. No. 4,448,979 also disclosehydroxy-containing compounds represented by the above general formulawherein R^(*) is ##STR10##

These compounds are prepared by the action of certain microorganisms onthe corresponding non-hydroxylated substrates. One such organismdescribed in U.S. Pat. No. 4,537,859 is of the genus Nocardia.

U.K. Patent 2,075,013 discloses hydroxy containing compounds representedby the above general formula wherein R^(*) is: ##STR11## wherein R¹ is Hor Me, and R² is H or acyl.

U.S. patent application Ser. No. 254,525 filed Oct. 6, 1988 discloses6-substituted compounds of the above general formula wherein R^(*) is:##STR12## wherein R is CH₂ OH, ##STR13## and R¹, R⁴, R⁷, R⁸ and R⁹ arebroadly defined organic moieties.

U.S. Pat. Nos. 4,604,472 and 4,733,003 disclose compounds of the aboveformula wherein R^(*) is: ##STR14## wherein X represents a hydrogen atomor a 2-methylbutyryl group, Y represents a hydrogen atom or a methylgroup and R¹ and R² are the same or different and each represents anoxygen atom or a group of formula ═N--OR³ where R³ is a hydrogen oralkyl moiety.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to HMG-CoA reductase inhibitors of structuralformulae (I) and (II). ##STR15## wherein:

R₁ is selected from:

(1) C₁₋₁₀ alkyl;

(2) substituted C₁₋₁₀ alkyl in which one or more substituent(s) isselected from

(a) halogen,

(b) hydroxy,

(c) C₁₋₁₀ alkoxy,

(d) C₁₋₅ alkoxycarbonyl,

(e) C₁₋₅ acyloxy,

(f) C₃₋₈ cycloalkyl,

(g) phenyl,

(h) substituted phenyl in which the substituents are X and Y,

(i) C₁₋₁₀ alkylS(0)_(n) in which n is 0 to 2,

(j) C₃₋₈ cycloalkylS(0)_(n),

(k) phenylS(0)_(n),

(l) substituted phenylS(0)_(n) in which the substituents are X and Y,and

(m) oxo;

(3) C₁₋₁₀ alkoxy;

(4) C₂₋₁₀ alkenyl;

(5) C₃₋₈ cycloalkyl;

(6) substituted C₃₋₈ cycloalkyl in which one substituent is selectedfrom

(a) C₁₋₁₀ alkyl

(b) substituted C₁₋₁₀ alkyl in which the substituent is selected from

(i) halogen,

(ii) hydroxy,

(iii) C₁₋₁₀ alkoxy,

(iv) C₁₋₅ alkoxycarbonyl,

(v) C₁₋₅ acyloxy,

(vi) phenyl,

(vii) substituted phenyl in which the substituents are X and Y

(viii) C₁₋₁₀ alkylS(0)_(n),

(ix) C₃₋₈ cycloalkylS(0)_(n),

(x) phenylS(0)_(n),

(xi) substituted phenylS(0)_(n) in which the substituents are X and Y,and

(xii) oxo,

(c) C₁₋₁₀ alkylS(0)_(n),

(d) C₃₋₈ cycloalkylS(0)_(n),

(e) phenylS(0)_(n),

(f) substituted phenylS(0)_(n) in which the substituents are X and Y,

(g) halogen,

(h) hydroxy,

(i) C₁₋₁₀ alkoxy,

(j) C₁₋₅ alkoxycarbonyl,

(k) C₁₋₅ acyloxy,

(l) phenyl, and

(m) substituted phenyl in which the substituents are X and Y;

(7) phenyl;

(8) substituted phenyl in which the substituents are X and Y;

(9) amino;

(10) C₁₋₅ alkylamino;

(11) di(C₁₋₅ alkyl)amino;

(12) phenylamino;

(13) substituted phenylamino in which the substituents are X and Y;

(14) phenyl C₁₋₁₀ alkylamino;

(15) substituted phenyl C₁₋₁₀ alkylamino in which the substituents are Xand Y;

(16) a member selected from

(a) piperidinyl,

(b) pyrrolidinyl,

(c) piperazinyl,

(d) morpholinyl, and

(e) thiomorpholinyl; and

(17) R₃ S in which R₃ is selected from

(a) C₁₋₁₀ alkyl,

(b) phenyl, and

(c) substituted phenyl in which the substituents are X and Y;

R₂ is H, CH₃, or CH₂ OH;

X and Y are independently selected from:

a) OH,

b) halogen,

c) trifluoromethyl,

d) C₁₋₃ alkoxy,

e) C₁₋₃ alkylcarbonyloxy,

f) phenylcarbonyloxy,

g) C₁₋₃ alkoxycarbonyl,

h) phenyloxycarbonyl,

i) hydrogen;

j) C₁₋₅ alkyl;

Z is selected from

(1) hydrogen;

(2) C₁₋₅ alkyl;

(3) substituted C₁₋₅ alkyl in which the substituent is selected from

(a) phenyl,

(b) dimethylamino, and

(c) acetylamino, and

(4) 2,3-hydroxypropyl;

halogen is C1 or F; a is a single bond or a double bond; andpharmaceutically acceptable salts of the compound (II) in which Z ishydrogen.

Except where specifically defined to the contrary, the terms "alkyl","alkenyl", "acyl" "aryloxy" and "alkoxy" include both the straight-chainand branched-chain species of the term.

One embodiment of this invention is the class of compounds of formulae(I) and (II) wherein:

R₁ is selected from:

(1) C₁₋₁₀ alkyl;

(2) substituted C₁₋₁₀ alkyl in which one or more substituent(s) isselected from

(a) halogen,

(b) hydroxy,

(c) C₁₋₁₀ alkoxy,

(d) C₁₋₅ alkoxycarbonyl,

(e) C₁₋₅ acyloxy,

(f) C₃₋₈ cycloalkyl,

(g) phenyl,

(h) substituted phenyl in which the substituents are X and Y, and

(i) oxo;

(3) C₃₋₈ cycloalkyl;

(4) substituted C₃₋₈ cycloalkyl in which one substituent is selectedfrom

(a) C₁₋₁₀ alkyl,

(b) substituted C₁₋₁₀ alkyl in which the substituent is selected from

(i) halogen,

(ii) hydroxy,

(iii) C₁₋₁₀ alkoxy

(iv) C₁₋₅ acyloxy,

(v) C₁₋₅ alkoxycarbonyl,

(vi) phenyl,

(vii) substituted phenyl in which the substituents are X and Y, and

(viii) oxo,

(c) halogen,

(d) hydroxy,

(e) C₁₋₁₀ alkoxy,

(f) C₁₋₅ alkoxycarbonyl,

(g) C₁₋₅ acyloxy,

(h) phenyl,

(i) substituted phenyl in which the substituents are X and Y;

(5) phenylamino;

(6) substituted phenylamino in which the substituents are X and Y;

(7) phenylC₁₋₁₀ alkylamino; and

(8) substituted phenyl C₁₋₁₀ alkylamino in which the substituents are Xand Y;

X and Y are independently selected from:

(a) OH,

(b) F,

(c) trifluoromethyl,

(d) C₁₋₃ alkoxy,

(e) hydrogen,

(f) C₁₋₅ alkyl.

In one subclass are the compounds of formulae (I) and (II) wherein R₁ isC₁₋₁₀ alkyl.

Illustrating this subclass are those compounds of formulae (I) and (II)wherein:

R₁ is 2 butyl or 2-methyl-2 butyl; and R₂ is H or CH₃.

Exemplifying this subclass are the following compounds:

(1) 6(R)-[2-[8(S) (2-methylbutyryloxy)-2(S),6-dimethyl-3-oxo-1,2,3,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy3,4,5,6-tetrahydro-2H-pyran-2-one;

(2) 6(R) [2 [8(S)-(2,2-dimethylbutyryloxy) 2(S),6-dimethyl -3-oxo1,2,3,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]4(R) hydroxy-3,4,5,6tetrahydro 2H-pyran-2-one;

(3) 6(R)-[Z-[8(S)-(Z-methylbutyryloxy)-Z(S)-methyl-3-oxo-1,2,3,7,8,8a(R) hexahydronaphthyl 1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro 2H-pyran-2-one;

(4) 6(R)-[2 [8(S)-(2,2-dimethylbutyryloxy) 2(S)-methyl -3-oxo1,2,3,7,8,8a(R) hexahydronaphthyl-1(S)]ethyl]-4(R) hydroxy3,4,5,6-tetrahydro-2H-pyran-2-one;

(5) 6(R)-[2 [8(S)-(2,2-dimethylbutyryloxy) 2(S),6(R)-dimethyl-3-oxo-1,2,3,5,6,7,8,8a(R)-octahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6 tetrahydro 2H pyran 2-one;

(6) 6(R)-[2-[8(S) (2,2-dimethylbutyryloxy) 2(S)-methyl -3oxo-1,2,3,5,6,7,8,8a(R)-octahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.

(7) 6(R) [2 [8(S)-(2-methylbutyryloxy) 2(S),6(R)-dimethyl-3-oxo-1,2,3,5,6,7,8,8a(R)-octahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2Hpyran 2 one;

(8) 6(R)-[2 [8(S) (2 methylbutyryloxy) 2(S)-methyl-3-oxo-1,2,3,5,6,7,8,8a(R)-octahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6 tetrahydro-2H-pyran-2-one.

The compounds of formulae (I) and (II) wherein R₂ is methyl and a is adouble bond, may be prepared from lovastatin or simvastatin or itsanalogs having a 6-methyl group by one of the following microbiologicalprocedures:

(a) adding the substrate to a growing culture of Nocardia autotrophicafor a suitable incubation period followed by isolation, andderivatization if desired;

(b) collecting a culture of the bioconverting microorganism andcontacting the collected cells with the substrate; or

(c) preparing a cell-free, enzyme-containing extract from the cells ofthe bioconverting microorganism and contacting this extract with thesubstrate.

Cultivation of the bioconverting microorganism of the genus Nocardia canbe carried out by conventional means in a conventional culture mediumcontaining nutrients well known for use with such microorganisms. Thus,as is well known, such culture media contain sources of assimilablecarbon and of assimilable nitrogen and often inorganic salts. Examplesof sources of assimilable carbon include glucose, sucrose, starch,glycerin, millet jelly, molasses and soybean oil. Examples of sources ofassimilable nitrogen include soybean solids (including soybean meal andsoybean flour), wheat germ, meat extracts, peptone, corn steep liquor,dried yeast and ammonium salts, such as ammonium sulphate. If required,inorganic salts, such as sodium chloride, potassium chloride, calciumcarbonate or phosphates, may also be included. Also, if desired, otheradditives capable of promoting the production of hydroxylation enzymesmay be employed in appropriate combinations. The particular cultivationtechnique is not critical to the process of the invention and anytechniques conventionally used for the cultivation of microorganisms mayequally be employed with the present invention. In general, of course,the techniques employed will be chosen having regard to industrialefficiency. Thus, liquid culture is generally preferred and the deepculture method is most convenient from the industrial point of view.

Cultivation will normally be carried out under aerobic conditions and ata temperature within the range from 20° to 37° C., more preferably from26° to 28° C.

Method (a) is carried out by adding the substrate to the culture mediumin the course of cultivation. The precise point during the cultivationat which the starting compound is added will vary depending upon thecultivation equipment, composition of the medium, temperature of theculture medium and other factors, but it is preferably at the time whenthe hydroxylation capacity of the microorganism begins to increase andthis is usually 1 or 2 days after beginning cultivation of themicroorganism. The amount of the substrate added is preferably from 0.01to 5.0% by weight of the medium, more preferably from 0.05 to 0.5%,e.g., from 0.05 to 0.1% by weight. After addition of the substrate,cultivation is continued aerobically, normally at a temperature withinthe ranges proposed above. Cultivation is normally continued for aperiod of from 1 to 2 days after addition of the substrate.

In method (b), cultivation of the microorganism is first carried outunder conditions such as to achieve its maximum hydroxylation capacity;this capacity usually reaches a maximum between 4 and 5 days afterbeginning the cultivation, although this period is variable, dependingupon the nature and temperature of the medium, the species ofmicroorganism and other factors. The hydroxylation capacity of theculture can be monitored by taking samples of the culture at suitableintervals, determining the hydroxylation capacity of the samples bycontacting them with a substrate under standard conditions anddetermining the quantity of product obtained and plotting this capacityagainst time as a graph. When the hydroxylation capacity has reached itsmaximum point, cultivation is stopped and the microbial cells arecollected. This may be achieved by subjecting the culture to centrifugalseparation, filtration or similar known separation methods. The wholecells of the cultivating microorganism thus collected, preferably, arethen washed with a suitable washing liquid, such as physiological salineor an appropriate buffer solution.

Contact of the collected cells of the microorganism of the genusNocardia with the substrate is generally effected in an aqueous medium,for example in a phosphate buffer solution at a pH value of from 5 to 9.The reaction temperature is preferably within the range from 20° to 45°C., more preferably from 25° to 30° C. The concentration of thesubstrate in the reaction medium is preferably within the range from0.01 to 5.0% by weight. The time allowed for the reaction is preferablyfrom 1 to 5 days, although this may vary depending upon theconcentration of the substrate in the reaction mixture, the reactiontemperature, the hydroxylation capacity of the microorganism (which may,of course, vary from species to species and will also, as explainedabove, depend upon the cultivation time) and other factors.

The cell free, enzyme containing extract employed in method (c) may beobtained by breaking down the whole cells of the microorganism obtainedas described in relation to method (b) by physical or chemical means,for example by grinding or ultrasonic treatment to provide adisintegrated cellular mass or by treatment with a surface active agentor an enzyme to produce a cellular solution. The resulting cell-freeextract is then contacted with the substrate under the same conditionsas are described above in relation to method (b).

The microorganism useful in the novel process of this invention is ofthe genus Nocardia. Of particular importance are the known strains ofmicroorganism, Nocardia autotrophica, subspecies canberrica, ATCC 35203of the culture MA 6181 and subspecies amethystina ATCC 35204 of theculture MA-6180 of the culture collection of Merck & Co., Inc., Rahway,N.J. A sample of the culture designated ATCC 35203 and ATCC 35204 isavailable in the permanent culture collection of the American TypeCulture Collection at 12301 Parklawn Drive, Rockville, Md. 20852.

After completion of the conversion reaction by any of the above methods,the desired compound can be directly isolated, separated or purified byconventional means. For example, separation and purification can beeffected by filtering the reaction mixture, extracting the resultingfiltrate with a water-immiscible organic solvent (such as ethylacetate), distilling the solvent from the extract, subjecting theresulting crude compound to column chromatography, (for example onsilica gel or alumina) and eluting the column with an appropriateeluent, especially in an HPLC apparatus.

Where the acyl moiety of formulae (I) or (II) is other than2-methylbutyryl or 2,2-dimethyl butyryl, the acyl moiety of lovastatinmay be hydrolyzed and the hydroxyl group reesterified with anappropriate alkanoyl halide following the procedure in U.S. Pat. No.4,444,784. The alkanoyl halide can be formed by standard transformationssuch as substitution with an alkyl halide or other appropriateelectrophile at an acidic C-H site on an available starting material.See for example U.S. Pat. No. 4,766,145 and allowed pending applicationsSer. No. 205,406 and Ser. No. 205,407 filed June 10, 1988.

Starting material (1) wherein R₂ is CH₂ OH may be prepared following theprocedures in copending application Ser. No. 254,525 filed Oct. 6, 1988.

The compounds of formulae (I) and (II) may also be prepared followingthe synthetic methodology in Scheme 1. ##STR16##

Starting material (1) is treated with a reagent suitable for protectingthe alcohol group at the lactone 4-position. Examples of suitablereagents are trialkylsilyl chlorides, dialkylarylsilyl chlorides anddihydropyran.

The diene (2) is treated with a halogenating agent such as phenylselenylchloride or bromide or phenylsulfinyl chloride, preferably phenylselenylchloride, in an approximately equimolar ratio in an inert solvent atabout -80° C., for approximately 20 minutes; illustrative of such inertsolvents are methylene chloride, ether and the like. After a standardworkup the product residue is dissolved in an ethereal solvent, chilledto about 0° C. and oxidized with an agent such as 30% hydrogen peroxideor a peroxy acid such as peroxybenzoic acid to yield a halohydrin analog(3).

Intermediate (3) is treated with a halide reducing agent such as atrialkyltin hydride or a triaryltin hydride, preferably tri-n-butyltinhydride and a radical initiator such as azobisisobutyronitrile (AIBN) inan inert solvent su:h as benzene at a temperature between 70° C. and100° C. preferably about 90° C. for 0.5 to 5 hours preferably 2 hours,to yield compound (4).

Compound (4) is treated with pyridinium chlorochromate (PCC) on aluminumoxide in toluene to yield the enone (5). Compound (5) is contacted withtrimethylsilyl trifluoromethanesulfonate and an amine to yield thetrimethylsilyl ether diene (6). Compound (6) is treated with palladiumacetate in acetonitrile to form dienone (7). Hydroxyl protecting groupsare removed by treatment with tetrabutyl ammonium fluoride and aceticacid in tetrahydrofuran to yield product (I).

Enone (5) can be converted to compounds of formula (I) wherein a is asingle bond by treatment with tetrabutyl ammonium fluoride in aceticacid.

Alternatively the compounds of formulae (I) can be prepared followingthe synthetic outline of Scheme 2. ##STR17##

Diene starting material (1) is converted to epoxides (8) and (9) bytreatment with m-chloroperoxybenzoic acid at about 0° C. The mixture ofepoxides is then contacted with tris(dibenzylideneacetone)-dipalladium(0) and triisopropoxy phosphine toyield the mixture of hydroxy dienes (10) and (11). This mixture is thenoxidized with PCC attenuated with 3,5 dimethylpyrazole to yield 5-onecompound (12) and product (I).

Enone (5) of Scheme 1 can also be formed from hydroxyl protected epoxide(9) or the mixture of epoxides (8) and (9) as shown below: ##STR18##

Compound (5) can then be employed in Scheme 1 to form product (I).

Where the reaction conditions of the above noted chemicaltransformations would be deleterious to the substituents in the8-acyloxy moiety, the acetoxy group can be employed as a protectinggroup which after the elaboration elsewhere in the molecule can beremoved by hydrolysis to give the 8 -hydroxy derivative which then canbe acylated according to the general procedures described in U.S. Pat.No. 4,661,483.

Where the product formed by the above described synthetic pathways isnot the desired form of that compound, then that product may besubjected to one or more further reactions such as hydrolysis,disilylation, salification, esterification, acylation, ammonolysis orlactonizaton by conventional methods.

Preferred metal salts are salts with alkali metals, such as sodium orpotassium, salts with alkaline earth metals, such as calcium ormagnesium, or salts with other metals such as aluminum, iron, zinc,copper, nickel or cobalt, of which the alkali metal, alkaline earthmetal, and aluminum salts are preferred, the sodium, calcium andaluminum salts being most preferred.

Preferred amino acids to form amino acid salts are basic amino acids,such as arginine, lysine, α,β-diaminobutyric acid or ornithine.

Preferred amines to form amine salts include dibenzylamine,ethylenediamine, morpholine, and tris(hydroxymethyl)aminomethane. Alsopreferred is ammonia to form the ammonium salt.

Esters are preferably the alkyl esters, such as the methyl, ethyl,propyl, isopropyl, butyl, isobutyl, or pentyl esters, of which themethyl ester is preferred. However, other esters such as phenyl-C₁₋₅alkyl, dimethylamino-C₁₋₅ alkyl, or acetylamino-C₁₋₅ alkyl may beemployed if desired.

Metal salts of the carboxylic acids of formula (II) may be obtained bycontacting a hydroxide or carbonate with the carboxylic acid of formula(II). The aqueous solvent employed is preferably water, or it may be amixture of water with an organic solvent, preferably an alcohol (such asmethanol or ethanol), a ketone (such as acetone), an aliphatichydrocarbon (such as hexane) or an ester (such as ethyl acetate). It ispreferred to use a mixture of a hydrophilic organic solvent with water.Such reactions are normally conducted at ambient temperature but theymay, if desired, be conducted with heating or cooling.

Amine salts of the carboxylic acids of formula (II) may be obtained bycontacting an amine in an aqueous solvent with the carboxylic acid offormula (II). Suitable aqueous solvents include water and mixtures ofwater with alcohols (such as methanol or ethanol), ethers (such asdiethyl ether and tetrahydrofuran), nitriles (such as acetonitrile) orketones (such as acetone); it is preferred to use aqueous acetone as thesolvent for this reaction. The reaction is preferably carried out at atemperature of ambient or below, more preferably a temperature of from5° to 10° C. The reaction immediately goes to completion. Alternatively,a metal salt of the carboxylic acid of formula (II) (which may have beenobtained as described above) can be dissolved in an aqueous solvent,after which a mineral acid salt (for example the hydrochloride) of thedesired amine is added, employing the same reaction conditions as whenthe amine itself is reacted with the carboxylic acid of formula (II) andthe desired product is then obtained by metathesis.

Amino acid salts of the carboxylic acids of formula (II) may be obtainedby contacting an amino acid in aqueous solution with the carboxylic acidof formula (II). Suitable aqueous solvents include water and mixtures ofwater with alcohols (such as methanol or ethanol) or ethers (such astetrahydrofuran).

Esters, preferably alkyl esters, of the carboxylic acids of formula (II)may be obtained by contacting the carboxylic acid of formula (II) withan appropriate alcohol, preferably in the presence of an acid catalyst,for example a mineral acid (such as hydrochloric acid or sulphuricacid), a Lewis acid (for example boron trifluoride) or an acidic ionexchange resin. The solvent employed for this reaction is not critical,provided that it does not adversely affect the reaction; suitablesolvents include the alcohol itself, benzene, chloroform, ethers and thelike. Alternatively, the desired product may be obtained by contactingthe carboxylic acid of formula (II) with a diazoalkane, in which thealkane moiety may be substituted or unsubstituted. This reaction isusually effected by contacting the acid with an ethereal solution of thediazoalkane. As a further alternative, the ester may be obtained bycontacting a metal salt of the carboxylic acid of formula (II) with ahalide, preferably an alkyl halide, in a suitable solvent; preferredsolvents include dimethylformamide, tetrahydrofuran, dimethylsulfoxideand acetone. Finally, esters may also be obtained from the lactone offormula (I) by reaction with an appropriate alkoxide in an absolutealkanol. All of the reactions for producing esters are preferablyeffected at about ambient temperature, but, if required by the nature ofthe reaction system, the reactions may be conducted with heating orcooling.

Lactones of the carboxylic acids of formula (I) may be obtained bylactonizing the carboxylic acids of formula (II) under ordinaryconditions known to one skilled in the art.

The intrinsic HMG CoA reductase inhibition activity of the claimedcompounds is measured in the in vitro protocol published in J. Med.Chem., 28, p. 347-358 (1985).

Representative of the intrinsic HMG-CoA reductase inhibitory activitiesof the claimed compounds is the relative potency of 6(R) [2-[8(S)-(2,2dimethylbutyryloxy) 2(S), 6-dimethyl 3-oxo1,2,3,7,8,8a(R)-hexahydronaphthyl -1(S)]ethyl]4(R)-hydroxy-3,4,5,6tetrahydro 2H-pyran-2-one which exhibited an IC₅₀ value of 2 ng/ml whencompared to an IC₅₀ value of 4.2 ng/ml for simvastatin. Compound 6(R)-[2[8(S)-(2,2-dimethylbutyryloxy)-2(S), 6(R) dimethyl 3oxo-1,2,3,5,6,7,8,8a(R)-octahydro-naphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6tetrahydro-2H-pyran 2-one; exhibited an IC₅₀ of 20ng/ml.

The compounds of this invention are useful as antihypercholesterolemicagents for the treatment of arteriosclerosis, hyperlipidemia, familialhypercholesterolemia and the like diseases in humans. They may beadministered orally or parenterally in the form of a capsule, a tablet,an injectable preparation or the like. It is usually desirable to usethe oral route. Doses may be varied, depending on the age, severity,body weight and other conditions of human patients but daily dosage foradults is within a range of from about 2 mg to 2000 mg (preferably 10 to100 mg) which may be given in two to four divided doses. Higher dosesmay be favorably employed as required.

The compounds of this invention may also be coadministered withpharmaceutically acceptable nontoxic cationic polymers capable ofbinding bile acids in a non reabsorbable form in the gastrointestinaltract. Examples of such polymers include cholestyramine, colestipol andpoly[methyl-(3-trimethylaminopropyl)imino-trimethylene dihalide]. Therelative amounts of the compounds of this invention and these polymersis between 1:100 and 1:15,000.

Included within the scope of this invention is the method of treatingarteriosclerosis, familial hypercholesterolemia or hyperlipidemia whichcomprises administering to a subJect in need of such treatment anontoxic, therapeutically-effective amount of the compounds of formulae(I) or (II) or pharmaceutical compositions thereof.

The following examples illustrate the preparation of the compounds ofthe formulae (I) and (II) and their incorporation into pharmaceuticalcompositions and as such are not to be considered as limiting theinvention set forth in the claims appended hereto.

EXAMPLE 1

Preparation of 6(R) [2-[8(S) (2,2-dimethylbutyryloxy) -2(S),6dimethyl-3-oxo-1,2,3,7,8,8a(R)-hexahydronaphthyl -1(S)]ethyl]-4(R)hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

Utilizing the general procedure for the bioconversion of sodium salt of7 [1,2'6'7,8,8a(R)-hexahydro-2(S), 6(R)-dimethyl 8(S)-(2,2dimethyl-butyryloxy)-1(S)-naphthyl]3(R), 5(R) dihydroxyheptanoic acid asdescribed in co-pending patent application Ser. No. 254,525, filed Oct.6, 1988 the above titled compound was isolated as a minor product.

The following media are utilized in the bioconversion reactionsdescribed below:

    ______________________________________                                                             Grams per liter                                                               distilled water                                          ______________________________________                                        Medium A                                                                      Yeast extract          4.0                                                    Malt extract           10.0                                                   Nutrient broth         4.0                                                    Dextrose               4.0                                                    pH 7.4                                                                        Medium sterilized for 20 min. at 121° C.                               Medium B                                                                      Dextrose               10.0                                                   Polypeptone            2.0                                                    Meat extract           1.0                                                    Corn steep liquor      3.0                                                    pH 7.0                                                                        Medium sterilized for 20 min. at 121° C.                               ______________________________________                                    

I. Culture Conditions and Bioconversion

A lyophilized tube of Nocardia autotrophica subsp. canberrica ATCC 35204(MA-6180) was used to inoculate 18×175 agar slants (Medium A) which wereincubated at 27° C. for 7 days. The slant culture was washed with 5 mlof sterile medium B and transferred to a 250 ml flask containing 50 mlof sterile medium B. This first stage seed was grown at 27° C. on a 220rpm shaker and, after 24 hours, 2 ml was transferred to another flask ofsterile medium B.

Grown under the above conditions, the second seed was used to start thebioconversion culture: 20 ml of the seed culture was placed in 400 ml ofsterile medium B in a 2L flask. After the culture had grown for 24hours, 80 mg of the sodium salt of 7-[1,2,6,7,8,8a(R)hexahydro-2(S),6(R) dimethyl-8(S)-(2,2 dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid was added to eachflask. The incubation was continued for 28 hours or until no7-[1,2,6,7,8,8a(R) hexahydro-2(S),6(R)-dimethyl8(S)-(2,2-dimethylbutyryloxy) -1(S) naphthyl]3(R),5(R)dihydroxyheptanoic acid could be detected by HPLC. The whole broth wasclarified by centrifugation followed by filtration through Whatman No. 2filter paper.

II. HPLC Methods

Aliquots of whole broth could be analyzed for7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S) -(2,2dimethylbutyryloxy)-1(S)-naphthyl]-3(R), 5(R) dihydroxyheptanoic a:idderivatives by HPLC. Filtered broth could be inJected directly (10 to 20μl) or after dilution with methanol. The compounds were separated onreverse phase columns utilizing a gradient from 35 to 45 percent aqueousacetonitrile at flow rates ranging between 1 and 3 ml/min. Addition ofglacial acetic acid or H₃ PO₄ (0.1 ml/L mobile phase) was required forthe separation of the free acids. Derivatives of 7[1,2,6,7,8,8a(R)-hexahydro -2(S),6(R) dimethyl-8(S)-(2,2dimethylbutyryloxy) -1(S) naphthyl]-3-(R),5(R)-dihydroxyheptanoic acidwere detected by monitoring the absorbance at 238 nm, as well as theabsorbance ratio of 238 nm/228 nm. The desired products, 6(R) [2-[8(S)(2-alkylacyloxy)-2(S),6-dimethyl-3-oxo-1,2,3,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R) -hydroxy-3,4,5,6tetrahydro-2H pyran 2 one, were detected by monitoring the absorbance at293 nm.

III. 6(R)-[2 [8(S)-(2,2-dimethylbutyryloxy) 2(S),6-dimethyl -3oxo-1,2,3,7,8,8a(R)hexahydronaphthyl-1(S)]-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro 2H-pyran2-one

Following the general procedure described above, the pH of the wholebroth from the bioconversion of twenty kilograms of the sodium salt of7-[1,2,6,7,8,8a(R) hexahydro 2(S),6(R)-dimethyl 8(S)-(2,2dimethylbutyryloxy) -1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid(12,700 liters) was adJusted to 4.0 with 2N sulfuric acid and was thenextracted with ethyl acetate (2×4500 1.). The whole broth extraction wasfollowed by an extraction of the ethyl acetate solution into 1N sodiumbicarbonate (20% by volume) and the aqueous extract was then washed withethyl acetate. To the aqueous extract was then addedmethylisobutylketone (MIBK, 570 1.) and the pH of the aqueous phaseadjusted to 3.1 using 7.2N sulfuric acid. The MIBK extract of theacidified aqueous phase was then separated from the aqueous phase whichwas then extracted with a second time MIBK (570 1.). The MIBK extractswere combined, filtered through diatomaceous earth, azeotropically driedand concentrated in vacuo to 870 liters. The MIBK solution was heated to95° C., and then treated with trifluoroacetic acid (0.9 1.) in MIBK (231.). After about 15 minutes, the mixture was cooled to 25° C. and washedsuccessively with 1N sodium bicarbonate (0.5 volumes) and water (2×0.5volumes). The organic phase was concentrated in vacuo and the residuedissolved in acetonitrile, which was then diluted to 30% acetonitrileusing 0.02M phosphate buffer at pH=7. Aliquots (1/3) which containapproximately 700 gm. of 6(R)-[2-[8(S) (2,2-dimethylbutyryloxy)6-hydroxymethyl -2(S)-methyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R) hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one werechromatographed over an SP-207 (300 1, brominated copolymer of styreneand divinylbenzene, Mitsubishi Co.) column. Elution withacetonitrile/buffer (30%, 37%, 47%, 57%,) and acetonitrile/water (67%)gave the above titled product and the 6-hydroxymethyl compound as amixture. The desired product may be further purified by removing most ofthe 6-hydroxymethyl compound by crystallization by dissolving themixture in isopropyl acetate (IPAC) or methyl-t-butyl ether (MTBE) andthen adding the solution to a non polar solvent (n-heptane, cyclohexaneor petroleum ether).

IV. Isolation of 6(R)-[2-[8(S) (2,2 dimethylbutyryloxy)-2(S),6-dimethyl-3-oxo-1,2,3,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R) hydroxy 3,4,5,6-tetrahydro-2H-pyran-2-one

The crystallization mother liquors from Step III were concentrated to anoil and then dissolved in toluene:methanol:acetonitrile (8:1:1, V:V:V)to a final volume of 100 ml. This solution was charged to a 10 litercolumn of Sephadex LH-20 (Pharmacia Inc.) equilibrated withhexane:toluene:methanol (3:1:1, V:V:V) and eluted with this solvent at aflow rate of 100 ml/min.

The desired compound eluted between 11 and 14 column volumes and therich cut eluant was concentrated to a solid. The product was furtherpurified by preparative reverse phase hplc on a C₁₈ column (21.4 mmID×30 cm) eluted with a linear gradient starting 10 minutes afterinjection from 25% acetonitrile in water to 75% acetonitrile in waterover 40 minutes at a flow rate of 10 ml/ min. The fractions containingthe desired product (eluting at 29 minutes) were combined andconcentrated to yield about 400 mg. of the desired product incrystalline form. ¹³ C NMR Data (CD₂ Cl₂, δ_(c) =53.8 ppm)

    ______________________________________                                        ppm             ppm    ppm                                                    ______________________________________                                         9.4            36.5    67.0                                                  10.6            36.8    76.0                                                  24.1            37.7   123.1                                                  24.3            39.0   124.5                                                  24.4            39.6   144.3                                                  24.9            42.7   154.9                                                  32.9            43.3   170.2                                                  33.4            63.1   177.6                                                                         203.4                                                  ______________________________________                                         catalyst by filtration and evaporation of the solvent afforded the title     compound. IR(film): 1718 cm.sup.-1, 1665 cm.sup.-1. MS(EI): m/z 434     (M.sup.+).

EXAMPLE 3

Preparation of 6(R)-[2-[8(S)-(2,2-dimethylbutyryloxy)-2(S), 6 dimethyl3-oxo 1,2,3,7,8,8a(R) hexahydrophthyl-1(S)]-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran 2 one

(a) 6(R)-[Z-[8(S)-(Z,Z-Dimethylbutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]-ethyl]-4(R)-(tbutyldimethylsilyloxy) 3,4,5,6-tetrahydro-2H-pyran-2-one (2')

Tert-Butyldimethylsilyl chloride (8 g, 52 mmol) was added to a stirredsolution of 6(R)-[2-[8(S) -(2,2Dimethylbutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6 tetrahydro 2H-pyran2-one (20 g, 48 mmol) and imidazole (6.8 g, 0.1 mol) in DMF (150 mL) at0° C. The resulting mixture was stirred at 0° C. for 5 minutes, thenwarmed to room temperature and stirred for 5 hours. TLC analysis of analiquot indicated that the reaction was complete. The reaction mixturewas poured into cold water and extracted with ether. The etherealextract was washed with dilute hydrochloric acid, water and 5% sodiumbicarbonate solution. After drying over MgSO₄, the organic extract wasfiltered and the filtrate was concentrated in vacuo to afford thedesired product as a colorless, viscous oil: NMR (CDCl₃) δ 0.84 (3H, t,J=7Hz), 0.89 (3 H, d, J= 7Hz), 0.90 (9H,s), 1.09 (3H, d, J=7Hz), 1.11(3H, s), 1.12 (3H, s), 4.30 (H, m), 4.60 (H, m), 5.33 (H, m), 5.51 (H,m), 5.77 (H, d of d, J=10, 6Hz), 5.98 (H, d, J=10 Hz).

(b) 6(R) [2-[5(S) Chloro 4a(S)-hydroxy-8(S) (2,2-dimethylbutyryloxy)-2(S),6(R) dimethyl 1,2,4a,5,6,7,8,8a(S)-octahydronaphthyl-1(S)]ethyl]4(R)-(t-butyldimethylsilyloxy)-3,4,5,6-tetrahydro 2H-pyran-2-one (3')

A solution of phenylselenyl chloride (10 g, 52 mmol) in methylenechloride (50 mL) was added dropwise to a stirred solution of compound 2'(25.2 g, 48 mmol) in methylene chloride (350 mL) cooled in a dry ice/ipropanol bath (-78° C.). The resulting mixture was stirred at 78° C. for20 minutes, poured into cold water (300 mL) and extracted with ethertwice (400 mL, then 150 mL). The combined extracts were dried (MgSO₄),filtered and concentrated to afford an oily residue which was dissolvedin tetrahydrofuran (300 mL). This solution was chilled in an ice bath(0° C.), and 30% hydrogen peroxide (15 mL) was added. The resultingmixture was stirred at 0° C. for 5 minutes, then warmed to roomtemperature and stirring continued for 1 hour. The reaction mixture waspoured into cold water and extracted with chloroform three times (400mL, then 2×100 mL). The combined extracts were dried (MgSO₄), filteredand concentrated to yield a residue which was purified by flashchromatography on a silica gel column. Elution with hexane:ethyl acetate(5:1/v:v) removed the impurities. Further elution with hexane:ethylacetate (4:1/v:v) provided the title compound as a pale yellow gum whichlater solidified on standing: mp 117+-8° C., NMR (CDCl₃) δ 0.075 (3H,s), 0.08 (3H, s), 0.85 (3H, t, J=7Hz), 0.88 (9H s) 0.89 (3H, d, J =7Hz),1.15 (3H, s), 1.16 (3H, s), 1.32 (3H, d, J =7Hz), 1.58 (2H, q, J =7Hz),3.39 (H, s), 4.05 (H, bs), 4.30 (H, m), 4.60 (H, m), 5.32 (H, m), 5.59(H, d, J=11 Hz), 5.79 (H, d of d, J=11, 6 Hz).

Anal. Calcd. for C₃₁ H₅₃ C10₆ Si: C, 63.61; H, 9.13.

Found: C, 63.80; H, 9.04.

(c) 6(R) [2 [4a(S) hydroxy 8(S)-(2,2-dimethylbutyryloxy) -2(S),6(R)dimethyl-1,2,4a,5,6,7,8,8a(S)-octahydronaphthyl -1(S)]ethyl]4(R)(t-butyldimethylsilyloxy) -3,4,5,6-tetrahydro 2H pyran-2 one (4')

Tributyltin hydride (7 06 m1, 26.25 mmol) and azobisisobutyronitrile(AIBN) (0.82 g, 5.0 mmol) were added to a magnetically stirred solutionof chlorohydrin 3' (8.78 g, 15 mmol) in benzene (100 ml). The resultingsolution was refluxed for 2 hours, cooled and concentrated in vacuo to aviscous yellow oil which was stirred with pet ether (200 ml) at -15° C.(ice/acetone bath) to provide 4' as a fluffy, colorless solid (6.9 g, mp97°-9° C.). The filtrate was extracted with CH₃ CN (4×50 ml) to removea11 of the prOduct contained in the pet ether. The CH₃ CN extracts werecombined and concentrated to a colorless oil which was purified by flashchromatography on a silica gel column. Elution with ethyl acetone/hexane(1:3/v:v) gave a colorless solid (1.0 g) which was stirred in pet ether(25 ml) at 0° C. to remove some tin residues. The mixture was filteredto provide the product 4' as a colorless solid. M.P 103°-4° C., nmr(CDCl₃) δ 0.07 (3H, s), 0.08 (3H, s), 0.88 (9H, s), 1.15 (3H, s), 1.16(3H, s), 1.20 (3H, d, J =7Hz), 2.78 (H, s), 4.28 (H, m), 4.58 (H, m),5.30 (H, m), 5.58 (H, d, J =10Hz), 5.67 (H, dd, J=10, 5 Hz).

Anal. Calcd. for C₃₁ H₅₄ O₆ Si: C, 67.59; H, 9.88.

Found: C. 67.20; H. 9.99.

(d) 6R-[2-[3 oxo 8(S) (2,2 dimethylbutyryloxy) 2(S)6-(R)-dimethyl-1,2,3,5,6,7,8,8a octahydronaphthyl1(S)]-ethyl]-4(R)-(t-butyldimethylsilyloxy) 3,4,5, -6tetrahydro-2H-pyran-2-One. (5')

7.2 g (12 mmol) of compound (4') was combined with 60 ml of toluene and42 g of pyridinium chlorochromate/aluminum oxide. The mixture wasstirred and heated on a steam bath for 20 minutes after which time tlcshowed the reaction to be complete. The mixture was cooled, filtered andthe solids washed with warm toluene (4×50 ml). The solvent wasevaporated to yield an amber gum. Nmr (CDCl₃) δ 0.073 (3H, s), 0.079(3H, s), 0.804 (3H, t, J=7 Hz), 0.881 (9H, s), 1.026 (2H, d, J=6 Hz),1.036 (3H, d, J =6 Hz), 1.10 (6H, br s), 2.55-2.66 (3H, m), 4.276 (H,m), 4.588 (H, m) 5.42 (H, m), 5.910 (H, d, J =1.5 Hz)

(e) 6(R)-[Z-[8(S)-(Z,Z-dimethylbutyryloxy)-Z(S),6(R)dimethyl -3-(trimethylsilyloxy)-1,2,6,7'8,8a(R) [-hexahydro-1(S)]ethyl]-4(R)-(t-butyldimethylsilyloxy),3,4,5,6-tetrahydro-2H-pyran-2 one. (6')

The amber gum product of Step 3d was dissolved in methylene chloride andcooled to 0° C. under argon. The solution was treated with triethylamine(7.2 ml, 50 mmol) followed by slow addition of trimethylsilyltrifluoromethanesulfonate (5.4 ml, 28 mmol) while maintaining thetemperature below 3° C. After stirring at 0° C. for 15 minutes (tlcshowed the reaction to be complete by 5 minutes) the dark solution wasdiluted with methylene chloride (100 ml), washed with sat. NaHCO₃ (100ml), dried and the solvent evaporated.

(f) 6(R)-[2-[8(S) (2,2-dimethylbutyryloxy) 2(S),6-dimethyl -3-oxo1,2,3,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(t-butyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-One.(7')

The dark-amber residue of Step (3e) was dissolved inacetonitrile/tetrahydrofuran. Palladium (II) acetate (3.0 g, 13.0 mmol)was added to the mixture and the mixture stirred at room temperature for22 hours, at which time tlc showed the reaction to be complete. Themixture was filtered through a 3 cm pad, of silica gel and then washedwith ethyl acetate (150 ml), and the solvent evaporated. Nmr (CDCl₃) δ0.076 (3H, s) 0.082 (3H, s) 0.752 (3H, t, J =7 Hz) 0.883 (9H, s) 1.033(3H, d, J =7 Hz) 1.059 (3H, s) 1.065 (3H, s) 1.804 (3H, s) 4.295 (H, m)4.606 (H, m) 5.408 (H, m) 5.781 (H, br s), 6.136 (H, br s).

(g) 6(R)-[2-[8(S) (2,2-dimethylbutyryloxy) 2(S),6-dimethyl -3oxo-1,2,3,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy 3,4,5,6tetrahydro 2H-furan one. (I)

The dark brown gum of Step (3f) was dissolved in tetrahydrofuran, and tothis was added a mixture of tetra-n-butyl ammonium fluoride (30 ml) andacetic acid (5.6 ml). The combined mixture was stirred at 50° C. for 4hours, cooled, diluted with ethyl ether (400 ml) washed with water(5×100 ml), dried and the solvent evaporated. The residue solidified toa brown mass. The brown mass was chromatographed on a 50 mm LP columnusing hexane-ethylacetate, 1:1 for the first 10 fractions (25 mlfractions) then 1:2 for 11, then 1:4. The titled product was found infractions 25-53, m.p. 160°-174° C. This chromatographed product was thenrecrystallized from ethyl acetate (30 ml)-hexane (30 ml). After dryingat 60° C. for 2 hours under a vacuum the titled product was obtainedwith M.P. 179°-180° C. Nmr (CDCl₃) δ 0.758 (3H, t, J =7.4 Hz) 1.035 (3H,d, J=7.4 Hz) 1.063 (3H, s), 1.069 (3H, s), 1.867 (3H, s), 2.63 (H, ddd,J =1.47, 3.64, 12.6 Hz), 2.749 (H, dd 4.94, 12,6 Hz) 4.398 (H, m), 4.645(H, m), 5.424 (H, m), 5.781 (H, brs), 6.138 (H, brs)

Anal. Calcd. for C₂₅ H₃₆ O₆ : C, 69.42; H, 8.39

Found: C, 69.73; H, 8.54

EXAMPLE 4

Preparation of 6(R) [2-[3-oxo-8(S) (2,2-dimethylbutyryloxy) -2(S),6(R)-dimethyl 1,2,3,5,6,7,8,8a-octahydronaphthyl-1(S)]ethyl]4(R)-hydroxy 2,4,5,6-tetrahydro-2-H-pyran-2-one.

A solution of compound (5') (500 mg, 0.9 mmol) of example 3 in aceticacid (42 ml) and water (15 ml) was heated at 70° C. for 3 hours. Aftercooling, the reaction mixture was diluted with water and extracted withether. The ethanol extract was washed with water five times, then washedwith aqueous sodium bicarbonate and brine. After drying and filtration,the filtrate was evaporated to afford a residue which was purified byflash chromatography on silica gel column. Elution of the column with30% of acetone in methylene chloride gave the title compound as a solid:mp 117°-8° C.; nmr (CDCl₃) δ 0.80 (3H, t, J=7 Hz), 1.02 (3H, d, J =7Hz), 1.04 (3H, d, J=7 Hz), 1.10 (6H, s), 2.64 (H, m of d, J=18 Hz), 2.72(H, d of d, J = 18, 4 Hz), 4 3H (H, m), 4.65 (H, m), 5.44 (H, m), 5.92(H, bs).

Anal. Calcd. for C₂₅ H₃₈ O₆ : C, 69.09; H, 8.81

Found: C, 68.85; H, 8.65

EXAMPLE 5-9

Following the procedure of Example 3 and substituting an equivalentamount of reactant (A) for simvastatin in step (a), the product (B) isformed.

    ______________________________________                                         ##STR19##                                                                     ##STR20##                                                                    Example                                                                       ______________________________________                                        5           R.sub.1 = 2-butyl, R.sub.2 = CH.sub.3 ;                           6           R.sub.1 = 2-butyl, R.sub.2 = H;                                   7           R.sub.1 = 2-methyl-2-butyl, R.sub.2 = H;                          8           R.sub.1 = 2-methyl-2-butyl, R.sub.2 - CH.sub.2 OH;                9           R.sub.1 = 2-butyl, R.sub.2 = CH.sub.2 OH.                         ______________________________________                                    

EXAMPLE 10 Preparation of Ammonium Salts of Compounds II

The lactone (1.0 mmol) from Example 1 is dissolved with stirring in 0.1NNaOH (1.1 mmol) at ambient temperature. The resulting solution is cooledand acidified by the dropwise addition of 1N HC1. The resulting mixtureis extracted with diethyl ether and the extract washed with brine anddried (MgSO₄). The MgSO₄ is removed by filtration and the filtratesaturated with ammonia (gas) to give a gum which solidified to providethe ammonium salt.

EXAMPLE 11 Preparation of Alkali and Alkaline Earth Salts of CompoundsII

To a solution of 42 mg of lactone from Example 1 in 2 ml of ethanol isadded 1 ml of aqueous NaOH (1 equivalent). After one hour at roomtemperature, the mixture is taken to dryness in vacuo to yield thedesired sodium salt.

In like manner, the potassium salt is prepared using one equivalent ofpotassium hydroxide, and the calcium salt, using one equivalent of CaO.

EXAMPLE 12 Preparation of Ethylenediamine Salts of Compounds II

To a solution of 0.50 g of the ammonium salt from Example 10 in 10 ml ofmethanol is added 0.75 ml of ethylenediamine. The methanol is strippedoff under vacuum to obtain the desired ethylenediamine salt.

EXAMPLE 13 Preparation of Tris(hydroxymethyl)aminomethane Salts ofCompounds II

To a solution of 202 mg of the ammonium salt from Example 10 in 5 ml ofmethanol is added a solution of 60.5 mg of tris(hydroxymethyl)aminomethane in 5 ml of methanol. The solvent is removed in vacuo toafford the desired tris(hydroxymethyl)aminomethane salt.

EXAMPLE 14 Preparation of L-Lysine Salts of Compounds II

A solution of 0.001 mole of L-lysine and 0.0011 mole of the ammoniumsalt from Example 10 in 15 ml of 85% ethanol is concentrated to drynessin vacuo to give the desired L-lysine salt.

Similarly prepared are the L-arginine, L-ornithine, and Nmethylglucamine salts.

EXAMPLE 15 Preparation of Tetramethylammonium Salts of Compounds II

A mixture of 68 mg of ammonium salt from Example 10 in 2 ml of methylenechloride and 0.08 ml of 24% tetramethylammonium hydroxide in methanol isdiluted with ether to yield the desired tetramethylammonium salt.

EXAMPLE 16 Preparation of methyl ESters of Compounds II

To a solution of 400 mg of lactone from Example 1 in 100 ml of absolutemethanol is added 10 ml 0.1M sodium methoxide in absolute methanol. Thissolution is allowed to stand at room temperature for one hour, then isdiluted with water and extracted twice with ethyl acetate. The organicphase is separated, dried (Na₂ SO₄), filtered and evaporated in vacuo toyield the desired methyl ester.

In like manner, by the use of equivalent amounts of propanol, butanol,isobutanol, t butanol, amylalcohol, isoamylalcohol,2-dimethylaminoethanol, benzylalcohol, 2-acetamidoethanol and the like,the corresponding esters are obtained.

EXAMPLE 17 Preparation Of Free Dihydroxy Acids

The sodium salt of the compound II from Example 11 is dissolved in Z mlof ethanol-water (1:1; v:v) and added to 10 ml of 1N hydrochloric acidfrom which the dihydroxy acid is extracted with ethyl acetate. Theorganic extract is washed once with water, dried (Na₂ SO₄), andevaporated in vacuo with a bath temperature not exceeding 30° C. Thedihydroxy acid derivative slowly reverts to the corresponding, parentlactone on standing, but is stable at a pH above 7.

EXAMPLE 18

As a specific embodiment of a composition of this invention, 20 mg oflactone from Example 1, is formulated with sufficient finely dividedlactose to provide a total amount of 580 to 590 mg to fill a size 0,hard-gelatin capsule.

What is claimed is:
 1. A compound represented by the followingstructural formulae (I) or (II): ##STR21## wherein: R₁ is selectedfrom:(1) C₁₋₁₀ alkyl; (2) substituted C₁₋₁₀ alkyl in which one or moresubstituent(s) is selected from(a) halogen, (b) hydroxy, (c) C₁₋₁₀alkoxy, (d) C₁₋₅ alkoxycarbonyl, (e) C₁₋₅ acyloxy, (f) C₃₋₈ cycloalkyl,(g) phenyl, (h) substituted phenyl in which the substituents are X andY, (i) C₁₋₁₀ alkylS(0)_(n) in which n is 0 to 2, (j) C₃₋₈cycloalkylS(0)_(n), (k) phenylS(0)_(n), (l) substituted phenylS(0)_(n)in which the substituents are X and Y, and (m) oxo; (3) C₁₋₁₀ alkoxy;(4) C₂₋₁₀ alkenyl; (5) C₃₋₈ cycloalkyl; (6) substituted C₃₋₈ cycloalkylin which one substituent is selected from(a) C₁₋₁₀ alkyl (b) substitutedC₁₋₁₀ alkyl in which the substituent is selected from(i) halogen, (ii)hydroxy, (iii) C₁₋₁₀ alkoxy, (iv) C₁₋₅ alkoxycarbonyl, (v) C₁₋₅ acyloxy,(vi) phenyl, (vii) substituted phenyl in which the substituents are Xand Y (viii) C₁₋₁₀ alkylS(0)_(n), (ix) C₃₋₈ cycloalkylS(0)_(n), (x)phenylS(0)_(n), (xi) substituted phenylS(0)_(n) in which thesubstituents are X and Y, and (xii) oxo, (c) C₁₋₁₀ alkylS(0)_(n), (d)C₃₋₈ cycloalkylS(0)_(n), (e) phenylS(0)_(n), (f) substitutedphenylS(0)_(n) in which the substituents are X and Y, (g) halogen, (h)hydroxy, (i) C₁₋₁₀ alkoxy, (j) C₁₋₅ alkoxycarbonyl, (k) C₁₋₅ acyloxy,(l) phenyl, and (m) substituted phenyl in which the substituents are Xand Y; (7) phenyl; (8) substituted phenyl in which the substituents areX and Y; (9) amino; (10) C₁₋₅ alkylamino; (11) di(C₁₋₅ alkyl)amino; (12)phenylamino; (13) substituted phenylamino in which the substituents areX and Y; (14) phenyl C₁₋₁₀ alkylamino; (15) substituted phenyl C₁₋₁₀alkylamino in which the substituents are X and Y; (16) a member selectedfrom(a) piperidinyl, (b) pyrrolidinyl, (c) piperazinyl, (d) morpholinyl,and (e) thiomorpholinyl; and (17) R₃ S in which R₃ is selected from(a)C₁₋₁₀ alkyl, (b) phenyl, and (c) substituted phenyl in which thesubstituents are X and Y; R₂ is H, CH₃, or CH₂ OH; X and Y areindependently selected from:a) OH, b) halogen, c) trifluoromethyl, d)C₁₋₃ alkoxy, e) C₁₋₃ alkylcarbonyloxy, f) phenylcarbonyloxy, g) C₁₋₃alkoxycarbonyl, h) phenyloxycarbonyl, i) hydrogen; j) C₁₋₅ alkyl; Z isselected from(1) hydrogen; (2) C₁₋₅ alkyl; (3) substituted C₁₋₅ alkyl inwhich the substituent is selected from(a) phenyl, (b) dimethylamino, and(c) acetylamino, and (4) 2,3-hydroxypropyl;halogen is C1 or F; a is asingle bond or a double bond; and pharmaceutically acceptable salts ofthe compound (II) in which Z is hydrogen.
 2. A compound of claim 1wherein:R₁ is selected from: .(1) C₁₋₁₀ alkyl; (2) substituted C₁₋₁₀alkyl in which one or more substituent(s) is selected from(a) halogen,(b) hydroxy, (c) C₁₋₁₀ alkoxy, (d) C₁₋₅ alkoxycarbonyl, (e) C₁₋₅acyloxy. (f) C₃₋₈ cycloalkyl, (g) phenyl, (h) substituted phenyl inwhich the substituents are X and Y, and (i) oxo; (3) C₃₋₈ cycloalkyl;(4) substituted C₃₋₈ cycloalkyl in which one substituent is selectedfrom(a) C₁₋₁₀ alkyl, (b) substituted C₁₋₁₀ alkyl in which thesubstituent is selected from(i) halogen. (ii) hydroxy, (iii) C₁₋₁₀alkoxy (iv) C₁₋₅ acyloxy, (v) C₁₋₅ alkoxycarbonyl, (vi) phenyl, (vii)substituted phenyl in which the substituents are X and Y, and (viii)oxo, (c) halogen, (d) hydroxy, (e) C₁₋₁₀ alkoxy, (f) C₁₋₅alkoxycarbonyl, (g) C₁₋₅ acyloxy, (h) phenyl, (i) substituted phenyl inwhich the substituents are X and Y; (5) phenylamino; (6) substitutedphenylamino in which the substituents are X and Y; (7) phenylC₁₋₁₀alkylamino; and (8) substituted phenyl C₁₋₁₀ alkylamino in which thesubstituents are X and Y; X and Y are independently selected from:(a)OH, (b) F, (c) trifluoromethyl, (d) C₁₋₃ alkoxy, (e) hydrogen, (f) C₁₋₅alkyl.
 3. A compound of claim 2 wherein: R₁ is C₁₋₁₀ alkyl.
 4. Acompound of claim 3 wherein: R₁ is 2-butyl or 2-methyl-2-butyl; R₂ is Hor CH₃.
 5. A compound of claim 4 selected from the group consistingof:(1)7-[1,2,3,7,8,8a(R)-hexahydro-2(S)-6-dimethyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (2)7-[1,2,3,7,8,8a(R)-hexahydro-2(S)-6-dimethyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (3)7-[1,2,3,7,8,8a(R)-hexahydro-2(S)-methyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (4)7-[1,2,3,7,8,8a(R)-hexahydro-2(S)-methyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (5)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S),6(R)-dimethyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (6)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S)-methyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (7)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S),6(R)-dimethyl-3oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (8)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S)-methyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 6. A hypocholesterolemic, hypolipidemic pharmaceutical compositioncomprising a nontoxic therapeutically effective amount of a compound ofclaim 1 and a pharmaceutically acceptable carrier.
 7. A composition ofclaim 6 wherein the therapeutically effective compound is selected fromthe group consisting of:(1)7-[1,2,3,7,8,8a(R)-hexahydro-2(S),6-dimethyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (2)7-[1,2,3,7,8,8a(R)-hexahydro-2(S),6-dimethyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (3)7-[1,2,3,7,8,8a(R)-hexahydro-2(S)-methyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (4)7-[1,2,3,7,8,8a(R)-hexahydro-2(S)-methyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid. (5)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S),6(R)-dimethyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (6)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S)-methyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (7)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S),6(R)-dimethyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (8)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S)-methyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 8. A hypocholesterolemic, hypolipidemic pharmaceutical compositioncomprising a nontoxic therapeutically effective amount of a compound ofclaim 1 in combination with a pharmaceutically acceptable nontoxiccationic polymer capable of binding bile acids in a non-reabsorbableform in the gastrointestinal tract and a pharmaceutically acceptablecarrier.
 9. A method of treating hypercholesterolemia comprising theadministration to a subject in need of such treatment a nontoxictherapeutically effective amount of a compound of claim
 1. 10. A methodof claim 9 wherein the therapeutically effective compound is selectedfrom the group consisting of:(1)7-[1,2,3,7,8,8a(R)-hexahydro-2(S),6-dimethyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (2)7-[1,2,3,7,8,8a(R)-hexahydro-2(S),6-dimethyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (3)7-[1,2,3,7,8,8a(R)-hexahydro-2(S)-methyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (4)7-[1,2,3,7,8,8a(R)-hexahydro-2(S)-methyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid. (5)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S),6(R)-dimethyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (6)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S)methyl-3-oxo-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (7)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S),6(R)-dimethyl-3-oxo-8(S)-L(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid; (8)7-[1,2,3,5,6,7,8,8a(R)-octahydro-2(S)-methyl-3-oxo-8(S)-(2-methylbutyryloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.